

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Activity

Cell

158, 1243-1253

DOI: [10.1016/j.cell.2014.08.023](https://doi.org/10.1016/j.cell.2014.08.023)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Potency needs constancy. <i>Nature</i> , 2014, 514, 442-443.	13.7	3
3	A constant threat for HIV: Fc engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome. <i>European Journal of Immunology</i> , 2015, 45, 2183-2190.	1.6	3
4	<sc>TRIM</sc>21: a cytosolic Fc receptor with broad antibody isotype specificity. <i>Immunological Reviews</i> , 2015, 268, 328-339.	2.8	78
5	A monoclonal antibody with anti- α -like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects. <i>Transfusion</i> , 2015, 55, 1501-1511.	0.8	11
6	Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice. <i>Cell Reports</i> , 2015, 13, 610-620.	2.9	38
7	Automated pipeline for rapid production and screening of HIV-specific monoclonal antibodies using <i>pichia pastoris</i> . <i>Biotechnology and Bioengineering</i> , 2015, 112, 2624-2629.	1.7	13
8	Mouse and human FcR effector functions. <i>Immunological Reviews</i> , 2015, 268, 25-51.	2.8	412
9	The role of Fc receptors in <sc>HIV</sc> prevention and therapy. <i>Immunological Reviews</i> , 2015, 268, 296-310.	2.8	41
10	Fc γ 3 receptor pathways during active and passive immunization. <i>Immunological Reviews</i> , 2015, 268, 88-103.	2.8	108
11	Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 160-169.	1.5	21
12	Structural analysis of Fc/Fc γ 3R complexes: a blueprint for antibody design. <i>Immunological Reviews</i> , 2015, 268, 201-221.	2.8	68
13	Animal models in HIV-1 protection and therapy. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 170-176.	1.5	49
14	Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines. <i>Frontiers in Immunology</i> , 2015, 6, 367.	2.2	44
15	Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent. <i>PLoS Pathogens</i> , 2015, 11, e1004966.	2.1	74
16	HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and are Commonly Detected in Plasma from HIV-infected Humans. <i>EBioMedicine</i> , 2015, 2, 1464-1477.	2.7	60
17	Immune Complexes: Not Just an Innocent Bystander in Chronic Viral Infection. <i>Immunity</i> , 2015, 42, 213-215.	6.6	20
18	Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient. <i>Journal of Immunological Methods</i> , 2015, 418, 61-65.	0.6	11
19	Antibody Effector Functions Mediated by Fc γ 3-Receptors Are Compromised during Persistent Viral Infection. <i>Immunity</i> , 2015, 42, 367-378.	6.6	59

#	ARTICLE	IF	CITATIONS
20	Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. <i>Journal of Virology</i> , 2015, 89, 8840-8854.	1.5	51
21	Requirement for Fc Effector Mechanisms in the APOBEC3/Rfv3-Dependent Neutralizing Antibody Response. <i>Journal of Virology</i> , 2015, 89, 4011-4014.	1.5	9
22	Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. <i>Cancer Immunology Research</i> , 2015, 3, 704-713.	1.6	111
23	Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. <i>Cell</i> , 2015, 162, 160-169.	13.5	171
24	The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases. <i>PLoS Pathogens</i> , 2015, 11, e1004717.	2.1	30
26	An ultrasensitive impedimetric glycan biosensor with controlled glycan density for detection of lectins and influenza hemagglutinins. <i>Chemical Communications</i> , 2015, 51, 7474-7477.	2.2	55
27	Can HIV Be Cured and Should We Try?. <i>Mayo Clinic Proceedings</i> , 2015, 90, 705-709.	1.4	5
28	Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. <i>Cell</i> , 2015, 161, 1035-1045.	13.5	228
29	Antibody responses to envelope glycoproteins in HIV-1 infection. <i>Nature Immunology</i> , 2015, 16, 571-576.	7.0	364
30	Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. <i>Molecular Immunology</i> , 2015, 67, 171-182.	1.0	263
31	Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. <i>Aids</i> , 2015, 29, 453-462.	1.0	24
32	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. <i>Nature</i> , 2015, 522, 487-491.	13.7	665
33	Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 12675-12680.	3.3	44
34	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015, 163, 988-998.	13.5	326
35	The Structural Role of Antibody N-Glycosylation in Receptor Interactions. <i>Structure</i> , 2015, 23, 1573-1583.	1.6	147
36	The evolution within us. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140235.	1.8	34
37	Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells. <i>Journal of Immunology</i> , 2015, 195, 4861-4872.	0.4	36
38	Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?. <i>Trends in Microbiology</i> , 2015, 23, 653-665.	3.5	97

#	ARTICLE	IF	CITATIONS
39	The role of Fc γ 3R interactions in IgG-mediated microbial neutralization. <i>Journal of Experimental Medicine</i> , 2015, 212, 1361-1369.	4.2	132
40	Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1187-1191.	0.5	6
41	HIV-1 prophylactic vaccines: state of the art. <i>Journal of Virus Eradication</i> , 2016, 2, 5-11.	0.3	12
43	Biophysical and Functional Characterization of Rhesus Macaque IgG Subclasses. <i>Frontiers in Immunology</i> , 2016, 7, 589.	2.2	32
44	Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization. <i>Frontiers in Microbiology</i> , 2016, 7, 1739.	1.5	6
45	Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. <i>PLoS Pathogens</i> , 2016, 12, e1005817.	2.1	119
46	NK Cells Expressing the Inhibitory Killer Immunoglobulin-Like Receptors (iKIR) KIR2DL1, KIR2DL3 and KIR3DL1 Are Less Likely to Be CD16+ than Their iKIR Negative Counterparts. <i>PLoS ONE</i> , 2016, 11, e0164517.	1.1	5
47	A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response. <i>PLoS Pathogens</i> , 2016, 12, e1005409.	2.1	49
48	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005520.	2.1	150
49	Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques. <i>Aids</i> , 2016, 30, 1543-1551.	1.0	47
50	Advances and hope for perinatal HIV remission and cure in children and adolescents. <i>Current Opinion in Pediatrics</i> , 2016, 28, 86-92.	1.0	19
51	Sweet characterisation of prostate specific antigen using electrochemical lectin α -based immunosensor assay and MALDI TOF/TOF analysis: Focus on sialic acid. <i>Proteomics</i> , 2016, 16, 3085-3095.	1.3	31
52	Dimeric Fc γ 3R Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG. <i>Journal of Immunology</i> , 2016, 197, 1507-1516.	0.4	90
53	Immunoregulatory functions of immune complexes in vaccine and therapy. <i>EMBO Molecular Medicine</i> , 2016, 8, 1120-1133.	3.3	57
54	Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. <i>Journal of Immunology</i> , 2016, 197, 4603-4612.	0.4	44
55	Naturally Occurring Fc-Dependent Antibody From HIV-Seronegative Individuals Promotes HIV-Induced IFN γ Production. <i>Scientific Reports</i> , 2016, 6, 37493.	1.6	1
56	The Role and Function of Fc γ 3 Receptors on Myeloid Cells. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	96
57	Accelerated actin filament polymerization from microtubule plus ends. <i>Science</i> , 2016, 352, 1004-1009.	6.0	172

#	ARTICLE	IF	CITATIONS
58	Highly individual patterns of virus-immune IgG effector responses in humans. <i>Medical Microbiology and Immunology</i> , 2016, 205, 409-424.	2.6	20
59	Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies. <i>Journal of Virology</i> , 2016, 90, 6127-6139.	1.5	117
60	Biphasic CD8 ⁺ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization. <i>Journal of Virology</i> , 2016, 90, 6276-6290.	1.5	23
61	Enhanced clearance of HIV-1 ⁺ infected cells by broadly neutralizing antibodies against HIV-1 in vivo. <i>Science</i> , 2016, 352, 1001-1004.	6.0	302
62	Monoclonal antibody therapy for Junin virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4458-4463.	3.3	50
63	Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research. <i>Journal of Translational Medicine</i> , 2016, 14, 44.	1.8	15
64	Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. <i>Annual Review of Immunology</i> , 2016, 34, 635-659.	9.5	500
65	Targeting Epstein-Barr virus ⁺ transformed B lymphoblastoid cells using antibodies with T-cell receptor ⁺ like specificities. <i>Blood</i> , 2016, 128, 1396-1407.	0.6	17
66	Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 823-834.	21.5	51
67	Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-9.	3.0	36
68	Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. <i>Science</i> , 2016, 353, 1045-1049.	6.0	129
69	Antibody-Dependent Cellular Cytotoxicity Activity of Effector Cells from HIV-Infected Elite and Viral Controllers. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1079-1088.	0.5	15
70	Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16068.	1.8	48
71	Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. <i>Journal of Virology</i> , 2016, 90, 10993-11006.	1.5	33
72	A Functional Role for Antibodies in Tuberculosis. <i>Cell</i> , 2016, 167, 433-443.e14.	13.5	461
73	Elimination of HIV-1-infected cells by broadly neutralizing antibodies. <i>Nature Communications</i> , 2016, 7, 10844.	5.8	201
74	Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies. <i>Scientific Reports</i> , 2016, 6, 37225.	1.6	22
75	Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1187-1197.	0.5	1

#	ARTICLE	IF	CITATIONS
76	Modulating Antibody Functionality in Infectious Disease and Vaccination. Trends in Molecular Medicine, 2016, 22, 969-982.	3.5	71
77	Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiology and Molecular Biology Reviews, 2016, 80, 989-1010.	2.9	93
78	Immunoglobulin Glycosylation Effects in Allergy and Immunity. Current Allergy and Asthma Reports, 2016, 16, 79.	2.4	34
79	The first 24h. Current Opinion in HIV and AIDS, 2016, 11, 561-568.	1.5	10
80	Cell-targeting antibodies in immunity to Ebola. Pathogens and Disease, 2016, 74, ftw021.	0.8	11
81	Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell, 2016, 165, 1609-1620.	13.5	130
82	Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. Cancer Cell, 2016, 29, 820-831.	7.7	135
83	Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination. Expert Review of Vaccines, 2016, 15, 719-729.	2.0	30
84	The improved antibody response against HIV-1 after a vaccination based on intrastuctural help is complemented by functional CD8+ T cell responses. Vaccine, 2016, 34, 1744-1751.	1.7	9
85	NK Cells in HIV Disease. Current HIV/AIDS Reports, 2016, 13, 85-94.	1.1	114
86	Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. Mucosal Immunology, 2016, 9, 1584-1595.	2.7	92
87	Engineering broadly neutralizing antibodies for HIV prevention and therapy. Advanced Drug Delivery Reviews, 2016, 103, 157-173.	6.6	17
88	Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa. Journal of Structural Biology, 2016, 194, 78-89.	1.3	44
89	Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. Mucosal Immunology, 2016, 9, 821-833.	2.7	22
90	Broadly Neutralizing Antibodies for HIV Eradication. Current HIV/AIDS Reports, 2016, 13, 31-37.	1.1	72
91	Ultrasensitive detection of influenza viruses with a glycan-based impedimetric biosensor. Biosensors and Bioelectronics, 2016, 79, 644-649.	5.3	76
92	Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. Mucosal Immunology, 2016, 9, 1549-1558.	2.7	47
93	Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. MAbs, 2016, 8, 761-774.	2.6	17

#	ARTICLE	IF	CITATIONS
94	Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. <i>Journal of Virology</i> , 2016, 90, 2021-2030.	1.5	53
95	Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. <i>Journal of Virology</i> , 2016, 90, 266-278.	1.5	92
96	Sensitive detection and glycoprofiling of a prostate specific antigen using impedimetric assays. <i>Analyst</i> , The, 2016, 141, 1044-1051.	1.7	41
97	HIV-1 resistance to neutralizing antibodies: Determination of antibody concentrations leading to escape mutant evolution. <i>Virus Research</i> , 2016, 218, 57-70.	1.1	14
98	Systems serology for evaluation of <scp>HIV</scp> vaccine trials. <i>Immunological Reviews</i> , 2017, 275, 262-270.	2.8	69
99	Use of broadly neutralizing antibodies for <scp>HIV</scp> prevention. <i>Immunological Reviews</i> , 2017, 275, 296-312.	2.8	131
100	Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies. <i>Journal of Virology</i> , 2017, 91, .	1.5	63
101	Anti-retroviral antibody Fc-mediated effector functions. <i>Immunological Reviews</i> , 2017, 275, 285-295.	2.8	46
102	Survivors Remorse: antibody-mediated protection against <scp>HIV</scp>. <i>Immunological Reviews</i> , 2017, 275, 271-284.	2.8	25
103	Antibody gene transfer with adeno-associated viral vectors as a method for <scp>HIV</scp> prevention. <i>Immunological Reviews</i> , 2017, 275, 324-333.	2.8	51
104	Beyond Viral Neutralization. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 760-764.	0.5	36
105	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. <i>Nature Medicine</i> , 2017, 23, 185-191.	15.2	399
106	Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. <i>Journal of Immunological Methods</i> , 2017, 443, 33-44.	0.6	158
107	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. <i>Journal of Virology</i> , 2017, 91, .	1.5	5
108	Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. <i>Aids</i> , 2017, 31, 1505-1517.	1.0	22
109	Signaling by Antibodies: Recent Progress. <i>Annual Review of Immunology</i> , 2017, 35, 285-311.	9.5	167
110	Antibody-mediated immunotherapy against chronic hepatitis B virus infection. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1768-1773.	1.4	32
111	Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir. <i>Journal of Virology</i> , 2017, 91, .	1.5	33

#	ARTICLE	IF	CITATIONS
112	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. <i>Journal of Virology</i> , 2017, 91, .	1.5	14
113	Progress in HIV-1 antibody research using humanized mice. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 285-293.	1.5	12
114	Divergent Requirement of Fc-Fc γ 3 Receptor Interactions for <i>In Vivo</i> Protection against Influenza Viruses by Two Pan-H5 Hemagglutinin Antibodies. <i>Journal of Virology</i> , 2017, 91, .	1.5	8
115	In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses. <i>Vaccine</i> , 2017, 35, 2042-2051.	1.7	9
116	CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. <i>Nature</i> , 2017, 543, 564-567.	13.7	224
117	Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity. <i>Mucosal Immunology</i> , 2017, 10, 814-826.	2.7	13
118	Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10172-10177.	3.3	42
119	One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells. <i>Scientific Reports</i> , 2017, 7, 9130.	1.6	25
120	Natural killer cells in HIV-1 infection and therapy. <i>Aids</i> , 2017, 31, 2317-2330.	1.0	90
121	Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges. <i>International Immunopharmacology</i> , 2017, 52, 44-50.	1.7	7
122	Immunological aspects of rabies: a literature review. <i>Archives of Virology</i> , 2017, 162, 3251-3268.	0.9	40
123	Non-neutralizing Antibodies Alter the Course of HIV-1 Infection <i>In Vivo</i> . <i>Cell</i> , 2017, 170, 637-648.e10.	13.5	111
124	Humanized Mouse Models for Human Immunodeficiency Virus Infection. <i>Annual Review of Virology</i> , 2017, 4, 393-412.	3.0	65
125	Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1. <i>Cell Host and Microbe</i> , 2017, 22, 207-216.	5.1	60
126	Fc γ 3 Receptor Function and the Design of Vaccination Strategies. <i>Immunity</i> , 2017, 47, 224-233.	6.6	148
127	Potent <i>In Vivo</i> NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. <i>Journal of Virology</i> , 2017, 91, .	1.5	31
128	Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope. <i>Archives of Toxicology</i> , 2017, 91, 1595-1612.	1.9	23
129	Broadly neutralizing antibodies: An approach to control HIV-1 infection. <i>International Reviews of Immunology</i> , 2017, 36, 31-40.	1.5	12

#	ARTICLE	IF	CITATIONS
130	Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins. <i>Journal of Virology</i> , 2017, 91, .	1.5	18
131	Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. <i>Journal of Infectious Diseases</i> , 2017, 215, S152-S159.	1.9	22
132	The Role and Function of Fc γ 3 Receptors on Myeloid Cells. , 2017, , 405-427.		8
133	Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success. <i>Frontiers in Immunology</i> , 2017, 7, 661.	2.2	11
134	Mouse Liver Sinusoidal Endothelium Eliminates HIV-Like Particles from Blood at a Rate of 100 Million per Minute by a Second-Order Kinetic Process. <i>Frontiers in Immunology</i> , 2017, 8, 35.	2.2	37
135	Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design. <i>Frontiers in Immunology</i> , 2017, 8, 780.	2.2	23
136	Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?. <i>Frontiers in Immunology</i> , 2017, 8, 950.	2.2	11
137	Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity. <i>Frontiers in Immunology</i> , 2017, 8, 1033.	2.2	17
138	Increasing the Clinical Potential and Applications of Anti-HIV Antibodies. <i>Frontiers in Immunology</i> , 2017, 8, 1655.	2.2	22
139	Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination. <i>Frontiers in Immunology</i> , 2017, 8, 1883.	2.2	13
140	A potent human neutralizing antibody Fc-dependently reduces established HBV infections. <i>ELife</i> , 2017, 6, .	2.8	81
141	Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. <i>PLoS Pathogens</i> , 2017, 13, e1006793.	2.1	20
142	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002435.	3.9	104
143	Systems serology: profiling vaccine induced humoral immunity against HIV. <i>Retrovirology</i> , 2017, 14, 57.	0.9	75
144	Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field. <i>Current HIV Research</i> , 2017, 15, 202-215.	0.2	28
145	HIV Reactivation after Partial Protection by Neutralizing Antibodies. <i>Trends in Immunology</i> , 2018, 39, 359-366.	2.9	6
146	Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors. <i>Aids</i> , 2018, 32, 443-450.	1.0	35
147	Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 366-373.	1.5	64

#	ARTICLE	IF	CITATIONS
148	Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges. <i>Journal of Virology</i> , 2018, 92, .	1.5	51
149	Clinical Potential of Prefusion RSV F-specific Antibodies. <i>Trends in Microbiology</i> , 2018, 26, 209-219.	3.5	42
150	Beyond binding: antibody effector functions in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 46-61.	10.6	516
151	Impact of HIV-1 Envelope Conformation on ADCC Responses. <i>Trends in Microbiology</i> , 2018, 26, 253-265.	3.5	64
152	Anti-HIV-1 antibody-dependent cellular cytotoxicity. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 160-166.	1.5	25
153	Humanized mouse models to study pathophysiology and treatment of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 143-151.	1.5	19
154	Antibody-dependent cellular cytotoxicity in HIV infection. <i>Aids</i> , 2018, 32, 2439-2451.	1.0	67
155	Antibody-mediated prevention and treatment of HIV-1 infection. <i>Retrovirology</i> , 2018, 15, 73.	0.9	53
156	Measuring the ability of HIV-specific antibodies to mediate trogocytosis. <i>Journal of Immunological Methods</i> , 2018, 463, 71-83.	0.6	32
157	Enhancing Fcγ3R-mediated antibody effector function during persistent viral infection. <i>Science Immunology</i> , 2018, 3, .	5.6	5
158	Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1. <i>Lancet HIV</i> , 2018, 5, e723-e731.	2.1	10
159	Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. <i>Nature Communications</i> , 2018, 9, 3999.	5.8	98
160	NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 2290.	2.2	79
161	Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 2429.	2.2	15
162	Antibody-mediated protection against Ebola virus. <i>Nature Immunology</i> , 2018, 19, 1169-1178.	7.0	127
163	Blocking the Exit: CHIKV Neutralizing Antibodies Nip Viral Egress in the Bud. <i>Cell Host and Microbe</i> , 2018, 24, 328-330.	5.1	0
164	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. <i>Nature Medicine</i> , 2018, 24, 1590-1598.	15.2	129
165	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. <i>Aids</i> , 2018, 32, 1749-1761.	1.0	11

#	ARTICLE	IF	CITATIONS
166	Targeting the Latent Reservoir for HIV-1. <i>Immunity</i> , 2018, 48, 872-895.	6.6	282
167	Dissecting Fcγ3R Regulation through a Multivalent Binding Model. <i>Cell Systems</i> , 2018, 7, 41-48.e5.	2.9	28
168	Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?. <i>Retrovirology</i> , 2018, 15, 52.	0.9	29
169	HIV-1 cell-to-cell transmission and broadly neutralizing antibodies. <i>Retrovirology</i> , 2018, 15, 51.	0.9	43
170	Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains. <i>Frontiers in Immunology</i> , 2018, 9, 618.	2.2	3
171	Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?. <i>Journal of Pathogens</i> , 2018, 2018, 1-9.	0.9	20
172	Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry. <i>Journal of Virology</i> , 2018, 92, .	1.5	31
173	Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. <i>Viruses</i> , 2018, 10, 333.	1.5	7
174	Immune Correlate-Guided HIV Vaccine Design. <i>Cell Host and Microbe</i> , 2018, 24, 25-33.	5.1	44
175	HIV Vaccine Efficacy Trials: RV144 and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 3-30.	0.8	6
176	Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. <i>MBio</i> , 2018, 9, .	1.8	82
177	Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. <i>Retrovirology</i> , 2018, 15, 58.	0.9	32
178	Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1007238.	2.1	18
179	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. <i>Cell Host and Microbe</i> , 2018, 24, 221-233.e5.	5.1	182
180	Antibodies and tuberculosis: finally coming of age?. <i>Nature Reviews Immunology</i> , 2018, 18, 591-596.	10.6	73
181	HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1006987.	2.1	71
182	Human Immunodeficiency Virus Vaccines. , 2018, , 400-429.e25.		0
183	The potential of engineered antibodies for HIV-1 therapy and cure. <i>Current Opinion in Virology</i> , 2019, 38, 70-80.	2.6	34

#	ARTICLE	IF	CITATIONS
184	Illuminating the virus life cycle with single-molecule FRET imaging. <i>Advances in Virus Research</i> , 2019, 105, 239-273.	0.9	11
185	TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. <i>EBioMedicine</i> , 2019, 45, 328-340.	2.7	22
186	Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. <i>Frontiers in Immunology</i> , 2019, 10, 1296.	2.2	211
187	Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses. <i>Frontiers in Immunology</i> , 2019, 10, 1529.	2.2	34
188	Binding affinities of human IgG1 and chimerized pig and rabbit derivatives to human, pig and rabbit Fc gamma receptor IIIA. <i>PLoS ONE</i> , 2019, 14, e0219999.	1.1	3
189	Boosting of Markers of Fc γ 3 Receptor Function in Anti-HIV Antibodies During Structured Treatment Interruption. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 842-852.	0.5	1
190	Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1. <i>Retrovirology</i> , 2019, 16, 31.	0.9	11
191	Fc Mediated Activity of Antibodies. <i>Current Topics in Microbiology and Immunology</i> , 2019, , .	0.7	4
192	Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections. <i>Vaccines</i> , 2019, 7, 103.	2.1	15
193	Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function. <i>Frontiers in Immunology</i> , 2019, 10, 697.	2.2	55
194	TRIM21 – From Intracellular Immunity to Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 2049.	2.2	85
195	Differential requirements for Fc γ 3R engagement by protective antibodies against Ebola virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20054-20062.	3.3	45
196	Multi-isotype Glycoproteomic Characterization of Serum Antibody Heavy Chains Reveals Isotype- and Subclass-Specific N-Glycosylation Profiles. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 686-703.	2.5	44
197	Differential contribution of education through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell activation and ADCC. <i>Journal of Leukocyte Biology</i> , 2019, 105, 551-563.	1.5	12
198	Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies. <i>Molecular Therapy</i> , 2019, 27, 650-660.	3.7	42
199	Differential ACPA Binding to Nuclear Antigens Reveals a PAD-Independent Pathway and a Distinct Subset of Acetylation Cross-Reactive Autoantibodies in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 9, 3033.	2.2	43
200	Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2019, 10, 1021.	2.2	8
201	Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 1023.	2.2	42

#	ARTICLE	IF	CITATIONS
202	Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1007819.	2.1	18
203	Immune Correlates of Disease Progression in Linked HIV-1 Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1062.	2.2	14
204	Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice. <i>Current HIV/AIDS Reports</i> , 2019, 16, 224-229.	1.1	11
205	IgG and Fc γ 3 Receptors in Intestinal Immunity and Inflammation. <i>Frontiers in Immunology</i> , 2019, 10, 805.	2.2	85
206	Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 1025.	2.2	37
207	Antibody responses to viral infections: a structural perspective across three different enveloped viruses. <i>Nature Microbiology</i> , 2019, 4, 734-747.	5.9	158
208	Impact of Myeloid Reservoirs in HIV Cure Trials. <i>Current HIV/AIDS Reports</i> , 2019, 16, 129-140.	1.1	24
209	The Antibodiome—Mapping the Humoral Immune Response to HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 169-179.	1.1	13
210	Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses. <i>Frontiers in Immunology</i> , 2019, 10, 332.	2.2	156
211	Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease. <i>Frontiers in Immunology</i> , 2019, 10, 548.	2.2	194
212	Serum IgM Glycosylation Associated with Tuberculosis Infection in Mice. <i>MSphere</i> , 2019, 4, .	1.3	13
213	Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus. <i>Viruses</i> , 2019, 11, 305.	1.5	32
214	Immune Complex Vaccination. <i>Current Topics in Microbiology and Immunology</i> , 2019, 423, 95-118.	0.7	6
215	Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-Fc γ 3R interaction on monocytes. <i>Science Immunology</i> , 2019, 4, .	5.6	60
216	Fc Receptors in Antimicrobial Protection. <i>Current Topics in Microbiology and Immunology</i> , 2019, 423, 119-150.	0.7	15
217	Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell-based therapeutics?. <i>Journal of Leukocyte Biology</i> , 2019, 105, 1253-1259.	1.5	15
218	IgG Fc Receptors: Evolutionary Considerations. <i>Current Topics in Microbiology and Immunology</i> , 2019, 423, 1-11.	0.7	18
219	IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. <i>PLoS Pathogens</i> , 2019, 15, e1008064.	2.1	66

#	ARTICLE	IF	CITATIONS
220	Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 253-264.	1.5	10
221	Neutralizing antibodies for HIV-1 prevention. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 318-324.	1.5	34
222	The FCGR2C allele that modulated the risk of HIV-1 infection in the Thai RV144 vaccine trial is implicated in HIV-1 disease progression. <i>Genes and Immunity</i> , 2019, 20, 651-659.	2.2	6
223	Establishment of a Novel Humanized Mouse Model To Investigate <i>In Vivo</i> Activation and Depletion of Patient-Derived HIV Latent Reservoirs. <i>Journal of Virology</i> , 2019, 93, .	1.5	24
224	Long-Term Persistence of Anti-HIV Broadly Neutralizing Antibody-Secreting Hematopoietic Cells in Humanized Mice. <i>Molecular Therapy</i> , 2019, 27, 164-177.	3.7	25
225	Harnessing Antibody-Dependent Cellular Cytotoxicity To Control HIV-1 Infection. <i>ACS Infectious Diseases</i> , 2019, 5, 158-176.	1.8	5
226	Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains. <i>Journal of Infectious Diseases</i> , 2020, 221, 756-765.	1.9	2
227	Engineering the interactions between a plant-produced HIV antibody and human Fc receptors. <i>Plant Biotechnology Journal</i> , 2020, 18, 402-414.	4.1	26
228	Steric Accessibility of the Cleavage Sites Dictates the Proteolytic Vulnerability of the Anti-HIV-1 Antibodies 2F5, 2G12, and PG9 in Plants. <i>Biotechnology Journal</i> , 2020, 15, e1900308.	1.8	10
229	Broadly neutralizing antibodies for the treatment and prevention of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 49-55.	1.5	49
230	Recent insights into Fc-mediated effector responses to HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 282-289.	1.5	11
231	CD4+ T Cells Induced by Tuberculosis Subunit Vaccine H1 Can Improve the HIV-1 Env Humoral Response by Intrastructural Help. <i>Vaccines</i> , 2020, 8, 604.	2.1	8
232	Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 316-323.	1.5	6
233	Broadly neutralizing antibodies potently inhibit cell-to-cell transmission of semen leukocyte-derived SHIV162P3. <i>EBioMedicine</i> , 2020, 57, 102842.	2.7	5
234	Immunological approaches to HIV cure. <i>Seminars in Immunology</i> , 2021, 51, 101412.	2.7	39
235	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18754-18763.	3.3	53
236	Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18002-18009.	3.3	44
237	The importance of semen leukocytes in HIV-1 transmission and the development of prevention strategies. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2018-2032.	1.4	8

#	ARTICLE	IF	CITATIONS
238	Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. <i>Nature</i> , 2020, 588, 485-490.	13.7	95
239	Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. <i>Immunologic Research</i> , 2020, 68, 325-339.	1.3	39
240	Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions. <i>Frontiers in Immunology</i> , 2020, 11, 590780.	2.2	72
241	Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. <i>Nature Communications</i> , 2020, 11, 5851.	5.8	42
242	The role of IgG Fc receptors in antibody-dependent enhancement. <i>Nature Reviews Immunology</i> , 2020, 20, 633-643.	10.6	340
243	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. <i>Nature</i> , 2020, 584, 353-363.	13.7	413
244	Considerations of Antibody Geometric Constraints on NK Cell Antibody Dependent Cellular Cytotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 1635.	2.2	20
245	Engineering antibody-based molecules for HIV treatment and cure. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 290-299.	1.5	6
246	Persons who inject drugs (PWID) retain functional NK cells, dendritic cell stimulation, and adaptive immune recall responses despite prolonged opioid use. <i>Journal of Leukocyte Biology</i> , 2021, 110, 385-396.	1.5	3
247	Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells. <i>EMBO Reports</i> , 2020, 21, e49351.	2.0	26
248	FcRn, but not Fc γ Rs, drives maternal-fetal transplacental transport of human IgG antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12943-12951.	3.3	55
249	The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1112.	2.2	44
250	An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	6
251	Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41. <i>Frontiers in Immunology</i> , 2020, 11, 1141.	2.2	23
252	Anti-HIV-1 Antibodies: An Update. <i>BioDrugs</i> , 2020, 34, 121-132.	2.2	7
253	Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 225-237.	1.8	5
254	Pathways towards human immunodeficiency virus elimination. <i>EBioMedicine</i> , 2020, 53, 102667.	2.7	12
255	Broadly Neutralizing Antibodies for HIV Prevention. <i>Annual Review of Medicine</i> , 2020, 71, 329-346.	5.0	49

#	ARTICLE	IF	CITATIONS
256	Noncanonical Functions of Antibodies. Trends in Immunology, 2020, 41, 379-393.	2.9	17
257	A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities. Journal of Virology, 2020, 94, .	1.5	4
258	Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity. Molecular Therapy - Methods and Clinical Development, 2021, 20, 204-217.	1.8	7
259	Broadly neutralizing antibodies for HIV-1 prevention and therapy. Seminars in Immunology, 2021, 51, 101475.	2.7	28
260	Differential and sequential immunomodulatory role of neutrophils and Ly6C ^{hi} inflammatory monocytes during antiviral antibody therapy. Emerging Microbes and Infections, 2021, 10, 964-981.	3.0	3
261	Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via Fcγ3R11b on Liver Sinusoidal Endothelial Cells by Endocytosis. Journal of Immunology, 2021, 206, 1284-1296.	0.4	6
262	Antibodies for Human Immunodeficiency Virus-1 Cure Strategies. Journal of Infectious Diseases, 2021, 223, S22-S31.	1.9	7
263	Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates. Frontiers in Immunology, 2021, 12, 623996.	2.2	10
264	CD34T+ Humanized Mouse Model to Study Mucosal HIV-1 Transmission and Prevention. Vaccines, 2021, 9, 198.	2.1	4
265	Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. Immunity, 2021, 54, 412-436.	6.6	23
266	Mechanisms and targets of Fcγ3-receptor mediated immunity to malaria sporozoites. Nature Communications, 2021, 12, 1742.	5.8	38
268	Production of HIV-1 Env-Specific Antibodies Mediating Innate Immune Functions Depends on Cognate Interleukin-21- Secreting CD4 ⁺ T Cells. Journal of Virology, 2021, 95, .	1.5	4
269	Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates. Science Translational Medicine, 2021, 13, .	5.8	23
270	Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir. Frontiers in Immunology, 2021, 12, 663919.	2.2	5
271	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell, 2021, 184, 1804-1820.e16.	13.5	297
272	Targeting Fc effector function in vaccine design. Expert Opinion on Therapeutic Targets, 2021, 25, 467-477.	1.5	17
273	Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic. Frontiers in Public Health, 2021, 9, 690017.	1.3	26
274	Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Nature Protocols, 2021, 16, 3639-3671.	5.5	29

#	ARTICLE	IF	CITATIONS
275	Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections. <i>Viruses</i> , 2021, 13, 1037.	1.5	20
276	Are Fc Gamma Receptor Polymorphisms Important in HIV-1 Infection Outcomes and Latent Reservoir Size?. <i>Frontiers in Immunology</i> , 2021, 12, 656894.	2.2	1
277	Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. <i>Cell Reports</i> , 2021, 35, 109167.	2.9	8
278	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. <i>Cell Reports Medicine</i> , 2021, 2, 100313.	3.3	56
280	Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. <i>Cell Reports Medicine</i> , 2021, 2, 100275.	3.3	64
281	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
282	Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants. <i>Retrovirology</i> , 2021, 18, 17.	0.9	7
283	Decay of Fc-dependent antibody functions after mild to moderate COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100296.	3.3	56
284	Identification of the predominant human NK cell effector subset mediating ADCC against HIV-infected targets coated with BNabs or plasma from PLWH. <i>European Journal of Immunology</i> , 2021, 51, 2051-2061.	1.6	6
285	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. <i>Vaccine</i> , 2021, 39, 3879-3891.	1.7	3
286	Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2021, 95, e0021921.	1.5	7
287	Bispecific Anti-HIV Immunoconjugates That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity. <i>Vaccines</i> , 2021, 9, 774.	2.1	5
288	Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2021, 95, e0079621.	1.5	6
289	Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01. <i>Frontiers in Immunology</i> , 2021, 12, 710012.	2.2	6
290	Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure. <i>EBioMedicine</i> , 2021, 70, 103518.	2.7	3
291	Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. <i>Nature</i> , 2021, 599, 465-470.	13.7	129
292	Passive immunization of the human vagina. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	1.4	2
293	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. <i>Immunity</i> , 2021, 54, 2143-2158.e15.	6.6	155

#	ARTICLE	IF	CITATIONS
295	Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis. <i>Frontiers in Immunology</i> , 2021, 12, 734304.	2.2	9
296	HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. <i>Frontiers in Immunology</i> , 2021, 12, 733958.	2.2	14
297	Tensorâ€structured decomposition improves systems serology analysis. <i>Molecular Systems Biology</i> , 2021, 17, e10243.	3.2	12
298	Interleukin-21 in Viral Infections. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9521.	1.8	9
300	Immunological perspectives on spatial and temporal vaccine delivery. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113966.	6.6	14
301	A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells. <i>STAR Protocols</i> , 2021, 2, 100851.	0.5	28
303	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	283
304	Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo. <i>Journal of Infectious Diseases</i> , 2016, 214, 612-616.	1.9	33
310	Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. <i>JCI Insight</i> , 2017, 2, e88226.	2.3	14
311	Tandem bispecific broadly neutralizing antibody â€” a novel approach to HIV-1 treatment. <i>Journal of Clinical Investigation</i> , 2018, 128, 2189-2191.	3.9	3
312	Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. <i>Journal of Clinical Investigation</i> , 2018, 129, 182-191.	3.9	69
313	Blocking HIV-1 replication: are Fcâ€FcÎ³ receptor interactions required?. <i>Journal of Clinical Investigation</i> , 2018, 129, 53-54.	3.9	4
314	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2020, 130, 5157-5170.	3.9	22
315	Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2016, 126, 415-423.	3.9	64
316	A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV. <i>PLoS ONE</i> , 2015, 10, e0136862.	1.1	17
317	FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-Î³ Receptors in Human B Cells. <i>PLoS ONE</i> , 2016, 11, e0152425.	1.1	11
318	AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. <i>PLoS Pathogens</i> , 2015, 11, e1005090.	2.1	77
319	Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. <i>PLoS Pathogens</i> , 2017, 13, e1006313.	2.1	23

#	ARTICLE	IF	CITATIONS
320	Un barrio marginado no es un barrio marginal. A propósito de Nazaret (Valencia). Revista De Dialectología Y Tradiciones Populares, 2016, 71, 151-171.	0.3	5
321	NK cell-based therapies for HIV infection: Investigating current advances and future possibilities. Journal of Leukocyte Biology, 2021, , .	1.5	4
322	Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. Human Vaccines and Immunotherapeutics, 2021, 17, 4328-4344.	1.4	13
323	Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity. Cell Reports Medicine, 2021, 2, 100412.	3.3	15
324	Antibody Responses and Functions in Defense against Viral Infection. , 2016, , 279-285.		1
326	Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. Retrovirology, 2021, 18, 35.	0.9	7
327	HIV prevention in a time of COVID-19: A report from the HIVR4P // Virtual conference 2021. AIDS Research and Human Retroviruses, 2021, , .	0.5	1
331	HIV-1 prophylactic vaccines: state of the art. Journal of Virus Eradication, 2016, 2, 5-11.	0.3	10
332	Neutralization and beyond: Antibodies and HIV-1 acquisition. Current Topics in Virology, 2018, 15, 73-86.	0.0	1
333	Human Immunodeficiency Virus 1 (HIV-1): Viral Latency, the Reservoir, and the Cure. Yale Journal of Biology and Medicine, 2020, 93, 549-560.	0.2	7
335	Engaging innate immunity in HIV-1 cure strategies. Nature Reviews Immunology, 2022, 22, 499-512.	10.6	39
337	Identification of HIV-Reservoir Cells With Reduced Susceptibility to Antibody-Dependent Immune Response. SSRN Electronic Journal, 0, , .	0.4	0
338	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe, The, 2022, 3, e203-e214.	3.4	33
339	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Cell Reports, 2022, 38, 110368.	2.9	82
340	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Reports, 2022, 38, 110199.	2.9	19
341	Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. Cell Host and Microbe, 2022, 30, 41-52.e5.	5.1	44
342	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. PLoS Pathogens, 2022, 18, e1010183.	2.1	8
343	Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells. Nature Communications, 2022, 13, 630.	5.8	19

#	ARTICLE	IF	CITATIONS
344	Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis. <i>Nature Communications</i> , 2022, 13, 662.	5.8	18
345	Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence. <i>Frontiers in Immunology</i> , 2022, 13, 796481.	2.2	7
349	Physiological Considerations for Modeling in vivo Antibody-Target Interactions. <i>Frontiers in Pharmacology</i> , 2022, 13, 856961.	1.6	11
350	Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance. <i>Frontiers in Immunology</i> , 2022, 13, 842746.	2.2	5
351	HIV-gp140-Specific Antibodies Generated From Indian Long-Term Non-Progressors Mediate Potent ADCC Activity and Effectively Lyse Reactivated HIV Reservoir. <i>Frontiers in Immunology</i> , 2022, 13, 844610.	2.2	3
352	Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. <i>Science Translational Medicine</i> , 2022, 14, eabn9243.	5.8	84
354	Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	14
355	Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis. <i>Frontiers in Immunology</i> , 2022, 13, 830482.	2.2	14
356	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses. <i>Journal of Virology</i> , 2022, , e0003422.	1.5	7
357	An exploration of how broadly neutralizing antibodies might induce HIV remission: the "vaccinal" effect. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 162-170.	1.5	6
358	Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients. <i>European Journal of Immunology</i> , 2022, 52, 1297-1307.	1.6	37
372	Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	6
373	NK Cells in Protection from HIV Infection. <i>Viruses</i> , 2022, 14, 1143.	1.5	3
374	Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response. <i>ELife</i> , 0, 11, .	2.8	10
375	Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. <i>Immunological Reviews</i> , 2022, 310, 6-26.	2.8	138
376	Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent. <i>Vaccines</i> , 2022, 10, 903.	2.1	3
378	Benchmarking computational methods for B-cell receptor reconstruction from single-cell RNA-seq data. <i>NAR Genomics and Bioinformatics</i> , 2022, 4, .	1.5	4
379	Avidity in antibody effector functions and biotherapeutic drug design. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 715-735.	21.5	65

#	ARTICLE	IF	CITATIONS
380	Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	6
382	HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6. <i>Virology Journal</i> , 2022, 19, .	1.4	3
384	Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
386	An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1850-1861.	3.2	7
387	Engineering the supernatural: monoclonal antibodies for challenging infectious diseases. <i>Current Opinion in Biotechnology</i> , 2022, 78, 102818.	3.3	2
388	HIV-1 Vpu restricts Fc-mediated effector functions in vivo. <i>Cell Reports</i> , 2022, 41, 111624.	2.9	8
389	A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm. <i>Clinical Infectious Diseases</i> , 2022, 75, S490-S497.	2.9	1
390	Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?. <i>Clinical Infectious Diseases</i> , 2022, 75, S530-S540.	2.9	4
391	Mapping the interplay between NK cells and HIV: therapeutic implications. <i>Journal of Leukocyte Biology</i> , 2023, 113, 109-138.	1.5	1
392	Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use. <i>Frontiers in Plant Science</i> , 0, 14, .	1.7	1
393	Antiviral neutralizing antibodies: from in vitro to in vivo activity. <i>Nature Reviews Immunology</i> , 2023, 23, 720-734.	10.6	8
394	Adeno-associated virus-vectored delivery of HIV biologics: the promise of a "single-shot" functional cure for HIV infection. <i>Journal of Virus Eradication</i> , 2023, 9, 100316.	0.3	2
395	Outsmarting Pathogens with Antibody Engineering. <i>Annual Review of Chemical and Biomolecular Engineering</i> , 2023, 14, 217-241.	3.3	2
396	Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design. <i>Npj Vaccines</i> , 2023, 8, .	2.9	6